Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kimi Dart

Facial Plastic Surgery Lake Jackson, TX Doctor of Osteopathy

NPI 1881887867 CMS profile 358471

215 Oak Dr S Ste E, Lake Jackson, TX 77566

Open in the dashboard

General payments

$3,508

59 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimi Dart of Lake Jackson, TX is reported in the CMS Open Payments database as having received $3,508 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $366 11
2024 General $262 6
2023 General $2,003 22
2022 General $59 3
2021 General $776 15
2019 General $43 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimi Dart
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Kimi Dart were reported at $366. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Kimi Dart Facial Plastic Surgery median Middle half National median
2019 $43 $225 $92–$651 $163
2020 $0 $132 $45–$323 $114
2021 $776 $186 $67–$558 $132
2022 $59 $218 $83–$594 $149
2023 $2,003 $237 $94–$564 $160
2024 $262 $233 $104–$575 $164
2025 $366 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,775 14 payments
  2. Inspire Medical Systems, Inc. $822 23 payments
  3. Galderma Laboratories, L.P. $370 5 payments
  4. Xoran Technologies $142 1 payment
  5. Aerin Medical Inc. $123 1 payment
  6. OptiNose US, Inc. $88 4 payments
  7. Acclarent, Inc $75 4 payments
  8. Medtronic, Inc. $40 2 payments
  9. ALK-Abello, Inc $26 2 payments
  10. Kerecis Limited $17 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,986 52 payments
  2. Travel and Lodging $1,502 5 payments
  3. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. SCOPIS ENT $936 3 payments
  2. INSPIRE $822 23 payments
  3. XPRESS ENT DILATION SYSTEM $612 7 payments
  4. CLARIFIX CRYOTHERAPY DEVICE $227 4 payments
  5. MiniCAT $142 1 payment
  6. VIVAER STYLUS $123 1 payment
  7. RHINAER STYLUS $123 1 payment
  8. Xhance $88 4 payments
  9. LATERA $71 3 payments
  10. SHAVER SYSTEM $51 2 payments
  11. Other $378 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

248

Median for Otolaryngology: 297

Drug cost

$3,694

Median for Otolaryngology: $6,314

Branded share of claims

16.5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 60 $1,444
Fluticasone Propionate Generic 44 $556
Ofloxacin Generic 21 $550
Fluocinolone Acetonide Oil Generic 12 $481
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 18 $180
Mupirocin Generic 19 $133
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $107
Doxycycline Hyclate Generic 15 $106
Lidocaine Hcl Viscous Lidocaine Hcl Brand 12 $75
Amoxicillin Generic 20 $35

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$29,149

Medicare's payments for the services billed

Medicare patients

131

Average age 74

Services billed

1,223

80 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 34%
Diabetes 31%
Chronic kidney disease 27%
Atrial fibrillation 23%
Depression 22%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record